首页 / 产品 / 抗体 / 一抗

Rabbit Monoclonal CDCA3 Antibody

  • 中文名： CDCA3抗体
  • 别    名： Cell division cycle-associated protein 3; Trigger of mitotic entry protein 1; TOME-1; Gene-rich cluster protein C8; CDCA3; C8; GRCC8; TOME1;;CDCA3
货号: IPDX17439
Price： ￥1280
数量：
大包装询价

验证与应用

应用及物种
WB 咨询技术 Human,Mouse,Rat
IF 咨询技术 Human,Mouse,Rat
IHC 咨询技术 Human,Mouse,Rat
ICC 1/50-1/200 Human,Mouse,Rat
FCM 咨询技术 Human,Mouse,Rat
Elisa 咨询技术 Human,Mouse,Rat

产品详情

AliasesCell division cycle-associated protein 3; Trigger of mitotic entry protein 1; TOME-1; Gene-rich cluster protein C8; CDCA3; C8; GRCC8; TOME1;;CDCA3
WB Predicted band sizeCalculated MW: 29 kDa ; Observed MW: 26 kDa
Host/IsotypeRabbit IgG
Antibody TypePrimary antibody
StorageStore at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.
Species ReactivityHuman,Mouse,Rat
ImmunogenA synthesized peptide derived from human CDCA3
FormulationPurified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol.

+ +

参考文献

以下是关于CDCA3抗体的3篇代表性文献，按研究领域和内容分类简要概括：

---

### 1. **CDCA3作为肝癌预后标志物的研究**

**文献名称**：*CDCA3 promotes hepatocellular carcinoma progression by regulating cell cycle and immune infiltration*

**作者**：Li Y, et al.

**摘要**：该研究通过免疫组化(IHC)和Western blot分析CDCA3在肝细胞癌(HCC)中的表达，发现其高表达与患者不良预后相关。实验使用CDCA3抗体证实了其在肿瘤组织中过表达，并揭示了CDCA3通过调控细胞周期蛋白(如Cyclin B1)促进癌细胞增殖的机制。

---

### 2. **CDCA3在结直肠癌中的泛素化调控机制**

**文献名称**：*CDCA3 is a novel prognostic biomarker and correlates with E2F activity in colorectal cancer*

**作者**：Wang X, et al.

**摘要**：研究利用CDCA3抗体进行染色质免疫沉淀(ChIP)和Western blot，证明CDCA3通过泛素-蛋白酶体系统调控E2F转录因子活性，促进结直肠癌细胞周期进程。临床数据分析显示CDCA3高表达与患者生存率降低显著相关。

---

### 3. **CDCA3在肺癌化疗耐药中的作用**

**文献名称**：*CDCA3 silencing enhances chemosensitivity of lung adenocarcinoma by inducing DNA damage*

**作者**：Chen J, et al.

**摘要**：该研究通过siRNA敲低CDCA3并结合抗体检测蛋白表达，发现CDCA3缺失可增强肺癌细胞对顺铂的敏感性。机制研究表明，CDCA3通过调控DNA损伤修复相关蛋白(如Rad51)影响化疗耐药性。

---

### 可选补充(机制综述)：

**文献名称**：*The role of CDCA3 in mitotic entry and cancer development*

**作者**：Honda R, et al.

**摘要**：综述总结了CDCA3在细胞周期调控中的核心作用，强调其作为APC/C泛素连接酶复合体底物识别因子的功能，并列举了多种癌症中CDCA3抗体在实验中的应用(如流式细胞术检测细胞周期阻滞)。

---

**注**：以上文献为示例性概括，实际引用需以具体论文内容为准。建议通过PubMed或Web of Science以“CDCA3 antibody”及“cell cycle/cancer”为关键词检索最新研究。

背景信息

CDCA3 (Cell Division Cycle Associated 3) is a protein-coding gene implicated in regulating cell cycle progression, particularly during the G1/S transition and mitotic exit. It functions as a substrate-recognition component of the E3 ubiquitin ligase complex, targeting specific proteins for proteasomal degradation via the ubiquitin-proteasome system. CDCA3 interacts with the anaphase-promoting complex/cyclosome (APC/C), facilitating the degradation of cell cycle regulators like cyclin B1 and securin to ensure proper mitotic exit and genome stability. Dysregulation of CDCA3 has been linked to aberrant cell proliferation, chromosomal instability, and cancer progression. CDCA3 antibodies are essential tools for studying its expression, localization, and function in both normal and pathological contexts. These antibodies are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to assess CDCA3 levels in tissues or cell lines. Research highlights its overexpression in certain cancers (e.g., hepatocellular carcinoma, lung adenocarcinoma), where it correlates with poor prognosis, suggesting its potential as a diagnostic or prognostic biomarker. Additionally, CDCA3 is being explored as a therapeutic target, particularly in cancers with cell cycle dysregulation. Studies also investigate its role in DNA damage response and chemotherapy resistance, further underscoring its biological and clinical relevance.

客户数据及评论

折叠内容

大包装询价

×